Research News
A new BrightFocus-funded study uncovers genetic clues that could point to new strategies for regrowing neurons in people living with glaucoma.
A BrightFocus-funded study examines how glaucoma affects a specific retinal cell involved in mood and sleep. This research could enhance treatment development and care for the individual as vision loss advances in glaucoma.
Driven by a desire to make a meaningful impact on public health, National Glaucoma Research grant recipient Dr. Bingrui Wang is developing glaucoma prediction technology and tools for early detection.
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
A new BrightFocus-funded glaucoma vision research study suggests that Black and Asian people receive a critical glaucoma screening test less frequently than others, which could delay sight-saving treatment.
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
In a first of its kind study, BrightFocus-funded researchers have identified a possible new way to improve drugs to treat glaucoma by studying a tiny part of the eye’s drainage system that plays a major role in eye pressure.
Researchers have found a way to block a “master switch” in the eye and the brain that controls inflammation, introducing a possible target for combatting glaucoma and other neurodegenerative diseases.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.
